The ERA registry annual report 2019: summary and age comparisons
EntityUAM. Departamento de Medicina
PublisherOxford University Press
10.1093/ckj/sfab273Clinical Kidney Journal 15.3 (2022): 452-472
ISSN2048-8505 (print); 2048-8513 (online)
Funded byThe ERA Registry is funded by the ERA. This article was written by R. Boenink et al. on behalf of the ERA Registry, which is an official body of the ERA. In addition, S.B. reports personal fees from AstraZeneca, outside the submitted work; A.D.-S. reports personal fees from Astellas and Fresenius, outside the submitted work; F.L. reports personal fees from MeditesPharma, outside the submitted work; R.P. reports grants from The Iceland Centre for Research, Landspitali University Hospital Research Fund and University of Iceland Research Fund, outside the submitted work; P.F. reports grants from Finska läkaresällskapet and Liv och Hälsa, outside the submitted work; M.F.S.R. reports personal fees from Baxter and Fresenius, outside the submitted work; A.O. reports grants from Sanofi, and personal fees from Astellas, AstraZeneca, Amicus, Bayes, Fresenius Medical Care and Idorsia, outside the submitted work; and K.J.J. reports grants from ERA, during the conduct of the study
Subjectsdialysis; epidemiology; ESRD; graft survival; kidney transplantation; patient survival; Medicina
NoteArtículo escrito por un elevado número de autores, solo se referencian el que aparece en primer lugar, y los autores pertenecientes a la UAM
Rights© The Author(s) 2021
Esta obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial 4.0 Internacional.
Data on renal replacement therapy (RRT) for end-stage renal disease were collected by the European Renal Association (ERA) Registry via national and regional renal registries in Europe and countries bordering the Mediterranean Sea. This article provides a summary of the 2019 ERA Registry Annual Report, including data from 34 countries and additional age comparisons. Methods: Individual patient data for 2019 were provided by 35 registries and aggregated data by 17 registries. Using these data, the incidence and prevalence of RRT, the kidney transplantation activity and the survival probabilities were calculated. In 2019, a general population of 680.8 million people was covered by the ERA Registry. Overall, the incidence of RRT was 132 per million population (p.m.p.). Of these patients, 62% were men, 54% were ≥65 years of age and 21% had diabetes mellitus as primary renal disease (PRD), and 84% had haemodialysis (HD), 11% had peritoneal dialysis (PD) and 5% had pre-emptive kidney transplantation as an initial treatment modality. The overall prevalence of RRT on 31 December 2019 was 893 p.m.p., with 58% of patients on HD, 5% on PD and 37% living with a kidney transplant. The overall kidney transplant rate was 35 p.m.p. and 29% of the kidney grafts were from a living donor. The unadjusted 5-year survival probability was 42.3% for patients commencing dialysis, 86.6% for recipients of deceased donor grafts and 94.4% for recipients of living donor grafts in the period 2010-14. When comparing age categories, there were substantial differences in the distribution of PRD, treatment modality and kidney donor type, and in the survival probabilities
Files in this item
This item appears in the following Collection(s)
Showing items related by title, author, creator and subject.
The Spanish Society of Nephrology (SENEFRO) commentary to the Spain GBD 2016 report: Keeping chronic kidney disease out of sight of health authorities will only magnify the problem Ortiz Arduán, Alberto; Sánchez Niño, María Dolores; Crespo-Barrio, Marta; De-Sequera-Ortiz, Patricia; Fernández-Giráldez, Elvira; García-Maset, Rafael; Macía-Heras, Manuel; Pérez-Fontán, Miguel; Rodríguez-Portillo, Mariano; Salgueira-Lazo, Mercedes; Sánchez-Álvarez, Emilio; Santamaría-Olmo, Rafael; Simal-Blanco, Fernando; Pino-Pino, María Dolores